Login to Your Account

Mitoconix Bio gets $20M for mitochondrial dysfunction in neurodegeneration

By Cormac Sheridan
Staff Writer

Tuesday, June 27, 2017

DUBLIN – Mitoconix Bio Ltd., an Israeli startup commercializing science that emerged from Stanford University's School of Medicine, raised $20 million in series A funding to take forward a first-in-class inhibitor of mitochondrial division for treating Huntington's disease and other neurodegenerative conditions.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription